Skip to content
Peptide research

Mazdutide

Also known as IBI362 · LY3305677 · OXM3
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

A dual GLP-1 and glucagon receptor agonist for weight loss and blood sugar control. Human evidence for weight loss and glucose control is strong, though long-term safety data are limited and liver benefit evidence is weak. Gastrointestinal side effects are common, heart rate can rise, and hypoglycemia is a risk at higher doses, while thyroid tumor risk remains theoretical. It is not an approved drug in the US; supply is unregulated research-grade product.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Mazdutide (IBI362) is a once-weekly injectable that activates two gut hormone receptors simultaneously -- GLP-1 and glucagon -- to achieve greater weight loss than GLP-1-only drugs like semaglutide. It is a lab-made version of oxyntomodulin, a natural hormone released by your gut after eating. Developed by Innovent Biologics and Eli Lilly, mazdutide became the world's first dual GLP-1/glucagon receptor agonist to receive regulatory approval when China's NMPA approved it for chronic weight management in June 2025.

How it works in the body

A dual GLP-1 and glucagon receptor agonist. The GLP-1 activity reduces appetite and improves blood sugar control, while the glucagon activity increases energy expenditure by stimulating fat burning in the liver. This dual mechanism targets both sides of the energy balance equation simultaneously.

Research overview

Mazdutide's dual mechanism provides appetite suppression and insulin support through GLP-1 activation, plus enhanced fat burning and increased energy expenditure through glucagon activation. In the pivotal Phase 3 GLORY-1 trial (NEJM, 2025), the 6 mg dose achieved 14.0% body weight reduction at 48 weeks compared to 0.3% weight gain with placebo in Chinese adults. A high-dose Phase 1 trial reached 21.0% weight loss at 20 weeks. Meta-analyses across seven randomized trials (680 participants) confirm reductions in weight, waist circumference, blood pressure, and cholesterol. Side effects are primarily gastrointestinal (nausea, diarrhea, vomiting) and generally mild-to-moderate. Most clinical data comes from Chinese populations, so broader global trial results are still pending.

Who researches Mazdutide?

Commonly researched by

  • People researching weight management options

    Studied for effects on body composition, appetite regulation, or metabolic rate.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

  • People researching blood sugar regulation

    Studied for effects on insulin sensitivity, glucose metabolism, or glycemic control.

Important considerations for

  • Those with Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • Those with History of pancreatitis

    High

    GLP-1 class effect. Monitor for pancreatitis signs and symptoms.

  • Those with Severe gastroparesis

    High

    GLP-1 component slows gastric emptying significantly.

  • Those who are pregnant or breastfeeding

    Absolute

    Investigational compound. No reproductive safety data.

Safety & interactions

Do not use if

  • Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • History of pancreatitis

    High

    GLP-1 class effect. Monitor for pancreatitis signs and symptoms.

  • Severe gastroparesis

    High

    GLP-1 component slows gastric emptying significantly.

General cautions

  • Pregnancy

    Absolute

    Investigational compound. No reproductive safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(9)

Rated by level of concern

  • Gastrointestinal adverse events: diarrhea (28-41%), nausea (21-25%), vomiting (12-16%), decreased appetite (27-31%), abdominal distension (4-12%)

    High

    PMID 37943529 (Diabetes Care 2024); PMID 40421736 (NEJM 2025); PMID 41407859 (Nature 2026)

  • Heart rate increase: 5-17 bpm elevation above baseline observed across doses

    Moderate

    PMID 36247927 (EClinicalMedicine 2022); PMID 40421736 (NEJM 2025)

  • Hypoglycemia risk: up to 16% at higher doses, especially when used with other antidiabetic agents; severe hypoglycemia rare

    Moderate

    PMID 37943529 (Diabetes Care 2024); PMID 41407859 (Nature 2026)

  • Injection site reactions: 4-6% incidence

    Low

    PMID 40421736 (NEJM 2025)

  • Immunogenicity: treatment-induced anti-mazdutide antibodies detected in 10-20% of participants, though no impact on efficacy or safety observed

    Low

    PMID 41028652 (Drugs 2025); PMID 40421736 (NEJM 2025)

  • Potential thyroid C-cell effects: class concern for GLP-1 receptor agonists; no C-cell hyperplasia or thyroid tumors observed in trials but long-term surveillance needed

    Theoretical

    PMID 41028652 (Drugs 2025); GLP-1 receptor agonist class labeling (FDA)

  • Cardiovascular effects: supraventricular extrasystoles and sinus tachycardia observed in small percentages; all asymptomatic and transient

    Low

    PMID 40421736 (NEJM 2025); PMID 36247927 (EClinicalMedicine 2022)

  • Limited long-term safety data: most evidence from trials of 20-48 weeks duration; post-marketing surveillance ongoing in China

    Moderate

    PMID 41028652 (Drugs 2025, Mazdutide: First Approval); PMID 40421736 (NEJM 2025); PMID 41407859 (Nature 2026)

  • Weight regain upon discontinuation: as with other GLP-1 agonists, weight regain expected after stopping treatment

    Moderate

    Class evidence: PMID 35441470 (Diabetes Obes Metab 2022, STEP-1 extension); PMID 38078870 (JAMA 2024, SURMOUNT-4)

Interaction summary(8)

Rated by direction with this peptide

  • Insulin (basal or prandial)

    CautionHigh

    Adding mazdutide to insulin raises hypoglycemia risk through additive glucose lowering; proactive insulin dose reduction and closer glucose monitoring are standard practice for GLP-1 receptor agonists and apply here. This is a class-level pharmacodynamic interaction rather than a mazdutide-specific drug-drug interaction study.

    GLP-1 receptor agonist class labeling (FDA); PMID 37943529 (Diabetes Care 2024)

  • Sulfonylureas (glimepiride, gliclazide, glipizide) and glinides

    CautionHigh

    Insulin secretagogues combined with mazdutide increase hypoglycemia risk through additive glucose lowering, and secretagogue dose reduction at initiation is the usual mitigation. In the phase 2 T2D trial, hypoglycemia with mazdutide monotherapy was 10% vs 8% with placebo.

    GLP-1 receptor agonist class labeling (FDA); PMID 37943529 (Diabetes Care 2024)

  • Orally administered drugs with narrow therapeutic index (levothyroxine, warfarin, digoxin, antiepileptics, immunosuppressants)

    CautionModerate

    Delayed gastric emptying from GLP-1 receptor agonism can alter the rate and, less often, the extent of oral absorption, so narrow-index oral agents warrant monitoring (INR, TSH, drug levels) around initiation and dose escalation. No dedicated drug-drug interaction studies for mazdutide specifically have been published; this is extrapolated from class labeling.

    GLP-1 receptor agonist class labeling (FDA, delayed gastric emptying)

  • General anesthesia and procedural sedation

    CautionModerate

    Retained gastric contents despite standard fasting have been documented with GLP-1 receptor agonists, raising pulmonary aspiration risk; the ASA and the 2024 multisociety guidance advise individualized management of weekly agents before elective procedures and treating patients with persistent GI symptoms as full-stomach. Guidance is class-based, not mazdutide-specific.

    American Society of Anesthesiologists guidance on GLP-1 receptor agonists (2023) and 2024 multisociety clinical practice guidance

  • Other GLP-1 receptor agonists, GLP-1/GIP co-agonists, and DPP-4 inhibitors

    CautionModerate

    Concurrent use duplicates incretin pharmacology with no established added benefit and compounded gastrointestinal and heart-rate effects; combining a GLP-1 receptor agonist with another incretin agent is not recommended in class labeling and guidelines.

    GLP-1 receptor agonist class labeling (FDA); PMID 41028652 (Drugs 2025)

  • SGLT2 inhibitors (empagliflozin, dapagliflozin)

    SynergisticLow

    Complementary, non-overlapping mechanisms give additive HbA1c and weight benefit with low intrinsic hypoglycemia risk, and guidelines support the combination in type 2 diabetes. Shared volume-depletion potential means fluid status deserves attention during GI adverse events. No mazdutide-specific combination trial has been published; the synergy is class- and guideline-level.

    ADA Standards of Care (combination therapy in type 2 diabetes)

  • Diuretics, ACE inhibitors and ARBs

    CautionModerate

    Mazdutide's high rate of diarrhea and vomiting can cause volume depletion, and superimposed diuretic or RAAS-blockade use raises the risk of acute kidney injury and symptomatic hypotension - a recognized class complication of GI adverse events rather than a direct pharmacologic interaction.

    GLP-1 receptor agonist class labeling (FDA, acute kidney injury warning); PMID 37943529 (Diabetes Care 2024)

  • Alcohol

    CautionTheoretical

    Alcohol can worsen gastrointestinal intolerance and independently increases hypoglycemia risk in patients also taking insulin or sulfonylureas.

    GLP-1 receptor agonist class labeling (FDA); general pharmacology of alcohol and insulin secretagogues

Known risks(9)

  • Gastrointestinal adverse events: diarrhea (28-41%), nausea (21-25%), vomiting (12-16%), decreased appetite (27-31%), abdominal distension (4-12%)

  • Heart rate increase: 5-17 bpm elevation above baseline observed across doses

  • Hypoglycemia risk: up to 16% at higher doses, especially when used with other antidiabetic agents; severe hypoglycemia rare

  • Injection site reactions: 4-6% incidence

  • Immunogenicity: treatment-induced anti-mazdutide antibodies detected in 10-20% of participants, though no impact on efficacy or safety observed

  • Potential thyroid C-cell effects: class concern for GLP-1 receptor agonists; no C-cell hyperplasia or thyroid tumors observed in trials but long-term surveillance needed

  • Cardiovascular effects: supraventricular extrasystoles and sinus tachycardia observed in small percentages; all asymptomatic and transient

  • Limited long-term safety data: most evidence from trials of 20-48 weeks duration; post-marketing surveillance ongoing in China

  • Weight regain upon discontinuation: as with other GLP-1 agonists, weight regain expected after stopping treatment

Drug interactions(6)

  • Insulin

    Increased risk of hypoglycemia when used with insulin or insulin secretagogues. Insulin adjustment may be required. In Phase 2 trials, hypoglycemia incidence was up to 16% at higher doses.

  • Sulfonylureas

    Enhanced hypoglycemic effect when co-administered. Monitor blood glucose closely and consider sulfonylurea dose reduction.

  • Metformin

    Generally safe to combine; 66.4% of Phase 2 trial participants were on metformin background therapy. No significant interaction reported but additive GI side effects possible.

  • Oral contraceptives

    GLP-1 receptor agonists delay gastric emptying, which may reduce absorption of oral medications. Consider monitoring efficacy of oral contraceptives.

  • Warfarin and oral anticoagulants

    Delayed gastric emptying may affect absorption kinetics. INR monitoring is recommended when starting or adjusting mazdutide.

  • Other GLP-1 receptor agonists (semaglutide, tirzepatide)

    Using mazdutide with other GLP-1 receptor agonists is not recommended: the overlapping mechanism adds risk of GI adverse events and hypoglycemia.

Research & benefits

Evidence base

Evidence Level
Strong
Total Studies
10

Supported by multiple Phase 1b, Phase 2, and Phase 3 randomized controlled trials, two systematic reviews/meta-analyses, and regulatory approval in China. The GLORY-1 Phase 3 trial (NEJM, 2025) provided pivotal evidence for weight management. A Phase 2 trial in type 2 diabetes (Diabetes Care, 2023) demonstrated glycemic and weight benefits. Meta-analyses (Frontiers in Endocrinology, 2024; Diabetes Obesity & Metabolism, 2026) confirm consistent efficacy across trials. US Phase 2 results were published in August 2026.

Researched for(7)

Rated by confidence in the evidence

  • Significant Weight Loss

    High

    Phase 3 trial showed up to 14% body weight loss at 48 weeks versus placebo.

    PMID 40421736 (N Engl J Med 2025;392:2215-2225); PMID 38092790 (Nat Commun 2023)

  • Glycemic Control

    High

    Human RCTs show significant HbA1c reduction; approved in China for type 2 diabetes.

    PMID 37943529 (Diabetes Care 2024); PMID 41407859 (Nature 2026, DREAMS-2); PMID 41028652 (Drugs 2025)

  • Dual Mechanism of Action

    Medium

    GLP-1 effects proven in humans; added energy-expenditure benefit is mechanism-based, not directly measured.

    PMID 41028652 (Drugs 2025, Mazdutide: First Approval); PMID 36247927 (EClinicalMedicine 2022)

  • Cardiovascular Risk Factor Improvement

    High

    Phase 3 trial showed improved cardiometabolic risk factors; no outcome trial yet for heart events.

    PMID 40421736 (N Engl J Med 2025)

  • Waist Circumference Reduction

    High

    Confirmed in multiple human trials, including phase 3 evidence versus placebo.

    PMID 40421736 (N Engl J Med 2025); PMID 36247927 (EClinicalMedicine 2022)

  • Convenient Dosing

    Medium

    Once-weekly dosing is confirmed in trials; convenience itself has not been separately tested.

    PMID 40421736 (N Engl J Med 2025); PMID 41407859 (Nature 2026)

  • Liver Enzyme Improvement

    Medium

    A randomized human trial found reduced ALT at 24 weeks; clinical liver outcomes remain unproven.

    PMID 38092790; Nature Communications 2023; https://www.nature.com/articles/s41467-023-44067-4

Benefits(7)

  • Significant Weight Loss

  • Glycemic Control

  • Dual Mechanism of Action

  • Cardiovascular Risk Factor Improvement

  • Waist Circumference Reduction

  • Convenient Dosing

  • Liver Enzyme Improvement

Key studies(5)

  1. Ji L, Jiang H, Bi Y, et al.

    New England Journal of Medicine

    2025

    Phase 3 RCT: At 48 weeks, mazdutide 4 mg and 6 mg achieved -11.0% and -14.0% body weight reduction vs +0.3% placebo in 610 Chinese adults with obesity/overweight.

  2. Zhang B, Cheng Z, Chen J, et al.

    Diabetes Care

    2023

    Phase 2 RCT (n=248): HbA1c reductions of -1.41% to -1.67% and dose-dependent weight loss up to -7.1% over 20 weeks. GI adverse events were mild-moderate and transient.

  3. Nalisa DL, Jiang H, et al.

    Frontiers in Endocrinology

    2024

    Meta-analysis of 7 RCTs (680 participants): Mean weight reduction -6.22% overall, -8.44% in non-diabetic participants. Significant reductions in blood pressure, cholesterol, and triglycerides.

  4. Azam MH, et al.

    Diabetes, Obesity and Metabolism

    2026

    Meta-analysis of 5 RCTs in non-diabetic obese adults: Mean body weight reduction -12.42%, absolute weight loss -9.76 kg, waist circumference decrease -7.98 cm.

  5. Shirley M

    Drugs

    2025

    Review of mazdutide's first regulatory approval in China (NMPA) for chronic weight management (June 2025) and type 2 diabetes (September 2025) as the world's first dual GLP-1/glucagon receptor agonist.

What research suggests over time

  • Weeks 2-4

    Phase 2 RCT

    Appetite reduction and early weight loss begin as dose titrates; GLP-1/glucagon dual mechanism active.

  • Months 2-3

    Phase 2 (Diabetes Care 2023)

    ~7% weight loss at 20 weeks at therapeutic doses; HbA1c reductions of 1.41-1.67% in T2DM.

  • Long-term

    Phase 3 (GLORY-1 NEJM 2025)

    Mean -11.0% to -14.0% body weight at 48 weeks across the GLORY-1 Phase 3 dose arms vs +0.3% placebo. Approved in China; US Phase 2 completed.

Regulation & availability

Why researchers look at it

Became the world's first approved dual GLP-1/glucagon agonist (China, June 2025), with a high-dose Phase 1 trial reaching 21% weight loss at just 20 weeks — potentially surpassing GLP-1-only drugs by adding glucagon-driven fat burning. Lilly's US Phase 2 trial is completed; US Phase 3 timing remains unconfirmed.

Estimated cost
No US-approved product; US Phase 2 completed.
FDA status
Mazdutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. US Phase 2 results were published in August 2026. US Phase 3 and approval dates remain unconfirmed. China-approved for obesity (June 2025) and type 2 diabetes (September 2025).
WADA status
GLP-1 receptor agonists are not currently on the WADA Prohibited List. However, athletes should verify current status as WADA reviews substances annually. Mazdutide's weight loss effects could potentially attract scrutiny in weight-class sports.
Prescribability
Mazdutide is an investigational drug. It is not FDA-approved, and in the US it is available only through clinical trials; it is not eligible for compounding. Approved in China as Xinermei for obesity (June 2025) and type 2 diabetes (September 2025).
Availability
Approved and commercially available in China as Xinermei (marketed by Innovent Biologics). Not yet available in the United States or Europe. Lilly's US Phase 2 obesity study, NCT06124807, conducted under master protocol NCT06143956, is completed. In the US it may be accessible through clinical trial enrollment.

International status

  • EU

    Not approved

  • US

    Not FDA-approved

  • Worldwide

    Approved in China (NMPA) for obesity (June 2025) and T2D (Sept 2025)

Regulatory timeline(11)

  1. 2020
    IND ApprovalInnovent Biologics received IND approval to begin clinical trials of mazdutide (IBI362) in China.
  2. 2021-2022
    Phase 1b TrialsMultiple Phase 1b dose-escalation trials conducted in China, UK, and Germany testing doses from 0.05 mg to 10 mg.
  3. 2022-2023
    Phase 2 TrialsPhase 2 trials in obesity (Nature Communications, 2023) and type 2 diabetes (Diabetes Care, 2023) demonstrated significant efficacy.
  4. 2023-2024
    Phase 3 GLORY-1 TrialPivotal Phase 3 trial in Chinese adults with obesity published in NEJM (2025), showing -11% to -14% weight loss at 48 weeks.
  5. February 2024
    NMPA Application Accepted (Obesity)China's NMPA accepted the application for chronic weight management indication.
  6. August 2024
    NMPA Application Accepted (T2D)China's NMPA accepted the application for type 2 diabetes indication.
  7. June 2025
    NMPA Approval (Obesity)Mazdutide (Xinermei) approved in China for long-term weight management in adults with BMI >= 28 or BMI >= 24 with comorbidities. First dual GLP-1/glucagon agonist approved worldwide for obesity.
  8. September 2025
    NMPA Approval (T2D)Mazdutide (Xinermei) approved in China for glycemic control in adults with type 2 diabetes.
  9. 2025-2026
    US Phase 2 Trials (Eli Lilly)Lilly's US Phase 2 obesity study, NCT06124807, conducted under master protocol NCT06143956, is completed. Lilly holds rights to mazdutide outside of China.
  10. 2026-2027 (projected)
    US Phase 3 TrialsPhase 3 trials in the US expected to begin pending Phase 2 results.
  11. 2028-2029 (projected)
    Potential US FDA ApprovalNDA submission estimated 2027-2028 with FDA approval potentially in 2028-2029. Priority review could accelerate timeline to late 2027.

Sources & FAQs

Research sources(9)

Frequently asked questions(4)

How does mazdutide differ from semaglutide (Wegovy/Ozempic)?

Mazdutide is a dual agonist targeting both GLP-1 and glucagon receptors, while semaglutide targets only GLP-1 receptors. The added glucagon receptor activation promotes increased hepatic fat oxidation and energy expenditure, potentially offering superior weight loss and metabolic benefits. Phase 3 data showed -14% weight loss at 48 weeks with the highest mazdutide dose.

What are the most common side effects of mazdutide?

The most common side effects are gastrointestinal: diarrhea (up to 41%), decreased appetite (up to 31%), nausea (up to 25%), and vomiting (up to 16%). These are generally mild to moderate, occur more frequently during dose escalation, and decline over time. Heart rate increases of 5-17 bpm have also been observed.

Is mazdutide available in the United States?

No. Mazdutide is currently only approved in China (as Xinermei). Lilly's US Phase 2 trial is completed. A US approval date is unconfirmed. Patients may access it through clinical trial enrollment.

Can mazdutide be used for conditions other than obesity and diabetes?

Mazdutide is currently being investigated for metabolic dysfunction-associated fatty liver disease (MAFLD), obstructive sleep apnea, and alcohol use disorder. A study also explored its potential to mitigate diabetes-associated cognitive dysfunction. These indications are still in early clinical evaluation.